{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:18:39Z","timestamp":1791566319698,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-01140-x","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:43:33Z","timestamp":1760622213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Angiotensin receptor-neprilysin inhibitor treatment in people with chronic obstructive pulmonary disease and heart failure"],"prefix":"10.1038","volume":"5","author":[{"given":"Wan-Hsuan","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Wen","family":"Shiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3290-1909","authenticated-orcid":false,"given":"Jheng-Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hsiang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khai-Chi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-8248","authenticated-orcid":false,"given":"Kuang-Ming","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"1140_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.trsl.2013.05.001","volume":"162","author":"SP Bhatt","year":"2013","unstructured":"Bhatt, S. P. & Dransfield, M. T. Chronic obstructive pulmonary disease and cardiovascular disease. Trans. l Res 162, 237\u2013251 (2013).","journal-title":"Trans. l Res"},{"key":"1140_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jacc.2017.05.043","volume":"70","author":"B Niemann","year":"2017","unstructured":"Niemann, B. et al. Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution: Part 3 of a 3-Part Series. J. Am. Coll. Cardiol. 70, 230\u2013251 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1140_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jjcc.2017.03.001","volume":"70","author":"K Onishi","year":"2017","unstructured":"Onishi, K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J. Cardiol. 70, 128\u2013134 (2017).","journal-title":"J. Cardiol."},{"key":"1140_CR4","doi-asserted-by":"publisher","first-page":"e006414","DOI":"10.1161\/CIRCHEARTFAILURE.119.006414","volume":"13","author":"MS Sabbah","year":"2020","unstructured":"Sabbah, M. S. et al. Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction. Circ. Heart Fail 13, e006414 (2020).","journal-title":"Circ. Heart Fail"},{"key":"1140_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/eurjhf\/hfn013","volume":"11","author":"NM Hawkins","year":"2009","unstructured":"Hawkins, N. M. et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur. J. Heart Fail 11, 130\u2013139 (2009).","journal-title":"Eur. J. Heart Fail"},{"key":"1140_CR6","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","volume":"64","author":"RJ Mentz","year":"2014","unstructured":"Mentz, R. J. et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J. Am. Coll. Cardiol. 64, 2281\u20132293 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1140_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/ejhf.600","volume":"18","author":"F Triposkiadis","year":"2016","unstructured":"Triposkiadis, F. et al. Reframing the association and significance of co-morbidities in heart failure. Eur. J. Heart Fail 18, 744\u2013758 (2016).","journal-title":"Eur. J. Heart Fail"},{"key":"1140_CR8","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","volume":"59","author":"S Ather","year":"2012","unstructured":"Ather, S. et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J. Am. Coll. Cardiol. 59, 998\u20131005 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1140_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.amjcard.2021.03.009","volume":"149","author":"S Jain","year":"2021","unstructured":"Jain, S. et al. Impact of Chronic Obstructive Pulmonary Disease in Heart Failure With Preserved Ejection Fraction. Am. J. Cardiol. 149, 47\u201356 (2021).","journal-title":"Am. J. Cardiol."},{"key":"1140_CR10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1513\/AnnalsATS.202107-823OC","volume":"19","author":"C Gulea","year":"2022","unstructured":"Gulea, C., Zakeri, R. & Quint, J. K. Differences in Outcomes between Heart Failure Phenotypes in Patients with Coexistent Chronic Obstructive Pulmonary Disease: A Cohort Study. Ann. Am. Thorac. Soc. 19, 971\u2013980 (2022).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"1140_CR11","doi-asserted-by":"crossref","unstructured":"Xu, S., Gu, Z., Zhu, W. & Feng, S. Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction. ESC Heart Fail 12, 799\u2013808 (2025).","DOI":"10.1002\/ehf2.14958"},{"key":"1140_CR12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med 371, 993\u20131004 (2014).","journal-title":"N. Engl. J. Med"},{"key":"1140_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez, E. J. et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N. Engl. J. Med 380, 539\u2013548 (2019).","journal-title":"N. Engl. J. Med"},{"key":"1140_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1161\/CIRCULATIONAHA.124.068774","volume":"150","author":"P Dewan","year":"2024","unstructured":"Dewan, P. et al. Effect of Sacubitril\/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF. Circulation 150, 272\u2013282 (2024).","journal-title":"Circulation"},{"key":"1140_CR15","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1002\/ejhf.3304","volume":"26","author":"MCH Lassen","year":"2024","unstructured":"Lassen, M. C. H. et al. Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril\/valsartan in PARAGON-HF. Eur. J. Heart Fail 26, 1762\u20131774 (2024).","journal-title":"Eur. J. Heart Fail"},{"key":"1140_CR16","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","volume":"44","author":"M Vaduganathan","year":"2023","unstructured":"Vaduganathan, M. et al. Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur. Heart J. 44, 2982\u20132993 (2023).","journal-title":"Eur. Heart J."},{"key":"1140_CR17","doi-asserted-by":"publisher","unstructured":"Liczek, M. et al. Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease. Adv. Respir Med. 86, https:\/\/doi.org\/10.5603\/ARM.a2018.0028 (2018).","DOI":"10.5603\/ARM.a2018.0028"},{"key":"1140_CR18","doi-asserted-by":"crossref","unstructured":"Topaloglu U., Palchuk M. B. Using a Federated Network of Real-World Data to Optimize Clinical Trials Operations. JCO Clin Cancer Inform 2018;1-10.","DOI":"10.1200\/CCI.17.00067"},{"key":"1140_CR19","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk, M. B. et al. A global federated real-world data and analytics platform for research. JAMIA Open 6, ooad035 (2023).","journal-title":"JAMIA Open"},{"key":"1140_CR20","unstructured":"FDA approves New Heart Failure Drug. American College of Cardiology. (2015, July 8). https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2015\/07\/08\/10\/00\/fda-approves-new-heart-failure-drug."},{"key":"1140_CR21","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1177\/1049732304265973","volume":"14","author":"PH Bailey","year":"2004","unstructured":"Bailey, P. H. The dyspnea-anxiety-dyspnea cycle-COPD patients\u2019 stories of breathlessness: \u201cIt\u2019s scary \/when you can\u2019t breathe. Qual. Health Res 14, 760\u2013778 (2004).","journal-title":"Qual. Health Res"},{"key":"1140_CR22","doi-asserted-by":"crossref","unstructured":"Ramon, M. A. et al. The dyspnoea-inactivity vicious circle in COPD: development and external validation of a conceptual model. Eur. Respir. J. 52, 1800079 (2018).","DOI":"10.1183\/13993003.00079-2018"},{"key":"1140_CR23","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1164\/rccm.200407-855OC","volume":"171","author":"F Pitta","year":"2005","unstructured":"Pitta, F. et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med 171, 972\u2013977 (2005).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"1140_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12890-023-02606-1","volume":"23","author":"H Chen","year":"2023","unstructured":"Chen, H. et al. Association between chronic obstructive pulmonary disease and cardiovascular disease in adults aged 40 years and above: data from NHANES 2013-2018. BMC Pulm. Med 23, 318 (2023).","journal-title":"BMC Pulm. Med"},{"key":"1140_CR25","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1136\/jcp.36.8.938","volume":"36","author":"PR Studdy","year":"1983","unstructured":"Studdy, P. R., Lapworth, R. & Bird, R. Angiotensin-converting enzyme and its clinical significance-a review. J. Clin. Pathol. 36, 938\u2013947 (1983).","journal-title":"J. Clin. Pathol."},{"key":"1140_CR26","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1161\/01.CIR.94.8.1941","volume":"94","author":"Z Nong","year":"1996","unstructured":"Nong, Z., Stassen, J. M., Moons, L., Collen, D. & Janssens, S. Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Circulation 94, 1941\u20131947 (1996).","journal-title":"Circulation"},{"key":"1140_CR27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2174\/1381612033455396","volume":"9","author":"A Molteni","year":"2003","unstructured":"Molteni, A. et al. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr. Pharm. Des. 9, 751\u2013761 (2003).","journal-title":"Curr. Pharm. Des."},{"key":"1140_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1183\/09031936.00060207","volume":"31","author":"RM W\u00f6sten-van Asperen","year":"2008","unstructured":"W\u00f6sten-van Asperen, R. M. et al. ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin. Eur. Respir. J. 31, 363\u2013371 (2008).","journal-title":"Eur. Respir. J."},{"key":"1140_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3109\/02770909909055418","volume":"36","author":"M Suzuki","year":"1999","unstructured":"Suzuki, M. et al. Effects of angiotensin-converting enzyme (ACE) inhibitors on oxygen radical production and generation by murine lung alveolar macrophages. J. Asthma 36, 665\u2013670 (1999).","journal-title":"J. Asthma"},{"key":"1140_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.etap.2018.05.002","volume":"60","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. The probable roles of valsartan in alleviating chronic obstructive pulmonary disease following co-exposure to cold stress and fine particulate matter. Environ. Toxicol. Pharm. 60, 230\u2013236 (2018).","journal-title":"Environ. Toxicol. Pharm."},{"key":"1140_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-017-0013-4","volume":"3","author":"O Iborra-Egea","year":"2017","unstructured":"Iborra-Egea, O. et al. Mechanisms of action of sacubitril\/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst. Biol. Appl 3, 12 (2017).","journal-title":"NPJ Syst. Biol. Appl"},{"key":"1140_CR32","doi-asserted-by":"publisher","first-page":"760035","DOI":"10.3389\/fcell.2021.760035","volume":"9","author":"T Jia","year":"2021","unstructured":"Jia, T. et al. Sacubitril Ameliorates Cardiac Fibrosis Through Inhibiting TRPM7 Channel. Front Cell Dev. Biol. 9, 760035 (2021).","journal-title":"Front Cell Dev. Biol."},{"key":"1140_CR33","doi-asserted-by":"publisher","first-page":"e021494","DOI":"10.1161\/JAHA.121.021494","volume":"10","author":"L Mooney","year":"2021","unstructured":"Mooney, L. et al. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. J. Am. Heart Assoc. 10, e021494 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"1140_CR34","doi-asserted-by":"publisher","first-page":"e019238","DOI":"10.1161\/JAHA.120.019238","volume":"10","author":"S Ehteshami-Afshar","year":"2021","unstructured":"Ehteshami-Afshar, S. et al. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J. Am. Heart Assoc. 10, e019238 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"1140_CR35","doi-asserted-by":"publisher","first-page":"e009078","DOI":"10.1161\/CIRCOUTCOMES.122.009078","volume":"16","author":"BA Bates","year":"2023","unstructured":"Bates, B. A. et al. Validity of International Classification of Diseases (ICD)\u221210 Diagnosis Codes for Identification of Acute Heart Failure Hospitalization and Heart Failure with Reduced Versus Preserved Ejection Fraction in a National Medicare Sample. Circ. Cardiovasc Qual. Outcomes 16, e009078 (2023).","journal-title":"Circ. Cardiovasc Qual. Outcomes"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01140-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01140-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01140-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:43:34Z","timestamp":1760622214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01140-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01140-x","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"427"}}